Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to define dose-limiting toxicity and determine preliminary evidence of
efficacy of carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients
with newly diagnosed multiple myeloma (MM).